The Galleri multi-cancer detection test made headlines when its landmark NHS trial failed to meet its primary endpoint, sending Grail's stock down nearly 50%. But does that mean Galleri is useless? Not exactly.
In this episode, Dr. Matt Kaeberlein breaks down what the NHS Galleri trial actually measured, why missing a primary endpoint doesn't tell the whole story, and what the results mean for three distinct groups: the general population, high-risk individuals, and people considering the test for themselves.Timestamps:0:00 — What is Galleri? Multi-cancer detection explained0:44 — Would Dr. Kaeberlein take the test? ($1,000 question)1:29 — Episode overview: defense, takedown, or something else?2:30 — How Galleri works: circulating tumor DNA and methylation3:23 — The core promise: early detection across 50+ cancer types4:20 — The NHS Galleri trial: 140,000 participants, 3 years5:15 — Trial results, the press release spin, and the stock drop5:59 — How OptiSpan currently uses Galleri in practice6:43 — Pre-trial take: not ready for population screening, but why?7:32 — The real risks: false positives, false negatives, and downstream consequences9:05 — What it takes to justify population-level screening10:48 — Inside the NHS trial design12:40 — Why the trial was set up to be difficult from the start13:29 — What the positive signals in the data actually suggest15:49 — High-risk individuals: does Galleri make sense for them?17:38 — Individual-level decision-making: what you need to consider18:33 — Sensitivity and specificity explained plainly22:07 — Walking through the math: false positives in the real world24:20 — Retesting after a positive signal: an open question25:00 — Sensitivity by cancer stage and aggressiveness25:45 — Final verdict: does Galleri have clinical value?27:25 — Dr. Kaeberlein's personal decision on taking the test
